U2Bio advances rapid, accurate disease
diagnosis through in vitro diagnostic device development.
Development and manufacturing of in vitro diagnostic medical device
Recognition
of GMP Conformity
(In vitro No. 4116)
U2PlexTM
Alpha-Thalassemia
Diagnostic Kit_A, B, C
(In vitro Jeheo No. 20-840,
No. 862, No. 861)
U2PlexTM
Q COVID-19
Fast Real-time
PCR Kit
(In vitro Jeheo 22-641)
U2Bio develops and manufactures in vitro diagnostic medical devices, continuously introducing products for the rapid and accurate diagnosis of various diseases.
The U2Plex™ Alpha-Thalassemia Diagnostics Kit for the diagnosis of alpha thalassemia analyzes major gene mutations to diagnose the disease more accurately and provides information usable for genetic counseling by distinguishing between homozygotes and heterozygotes.
In addition, the U2Plex™Q COVID-19 Fast Real-time PCR Kit rapidly detects COVID-19 virus genes in various specimens and contributes to the response to infectious diseases by providing results within approximately 45 minutes through RT-PCR-based analysis.
U2Bio will continue to advance diagnostic technology through continuous research and development. We will contribute to the improvement of human health by building a safer and more reliable medical environment and enhancing the efficiency and reliability of disease diagnosis.